


Supplementary Figure 3. Quality metrics of plasma samples



A, Plasma volume of analyzed samples in the NAC-treated and NAC-naïve cohorts. **B**, Amount of plasma cell-free DNA (cfDNA) extracted from samples in the NAC-treated and NAC-naïve cohorts. **C**, Library input for the NAC-treated and NAC-naïve cohorts. **D**, Plasma volume of analyzed samples collected before radical cystectomy (RC) in the NAC-naïve cohort separated by ctDNA status and whether the patient had metastatic relapse within 12 months after RC for ctDNA negative samples. **E**, Amount of cfDNA extracted from samples collected before RC in the NAC-naïve cohort separated by ctDNA status and whether the patient had metastatic relapse within 12 months after RC for ctDNA negative samples. **F**, Library input for samples collected before RC in the NAC-naïve cohort separated by ctDNA status and whether the patient had metastatic relapse within 12 months after RC for ctDNA negative samples.